Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$2.95 +1.7%	$2.87	$2.46 ▼ $4.15	$252.46M	0.17	308,463 shs	313,062 shs
CLSD Clearside Biomedical	$0.82 -5.0%	$0.87	$0.70 ▼ $1.65	$63.70M	2.11	341,253 shs	293,984 shs
CMPX Compass Therapeutics	$2.11 +1.0%	$1.90	$0.77 ▼ $4.08	$291.78M	1.4	922,864 shs	662,949 shs
TERN Terns Pharmaceuticals	$3.01 -0.3%	$2.80	$1.87 ▼ $11.40	$262.88M	-0.16	1.53 million shs	527,217 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	+1.72%	+1.72%	+2.08%	-6.65%	-19.40%
CLSD Clearside Biomedical	-5.02%	-6.69%	-2.61%	-8.92%	-39.28%
CMPX Compass Therapeutics	+0.96%	+0.48%	+8.76%	-28.96%	+43.54%
TERN Terns Pharmaceuticals	-0.33%	-4.44%	+3.08%	-19.95%	-49.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.5248 of 5 stars	3.3	2.0	0.0	2.4	2.5	1.3
CLSD Clearside Biomedical	1.9694 of 5 stars	3.5	5.0	0.0	1.7	0.0	0.0
CMPX Compass Therapeutics	3.9919 of 5 stars	4.6	3.0	0.0	3.5	5.0	0.0
TERN Terns Pharmaceuticals	4.2145 of 5 stars	3.3	2.0	4.1	4.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	103.39% Upside
CLSD Clearside Biomedical	3.00	Buy	$4.80	485.58% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	522.04% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	419.10% Upside

Current Analyst Ratings Breakdown

Latest CLSD, CMPX, AVIR, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$6.65 per share	N/A
CLSD Clearside Biomedical	$3.76M	16.92	N/A	N/A	($0.25) per share	-3.28
CMPX Compass Therapeutics	$850K	343.27	N/A	N/A	$1.17 per share	1.80
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$135.96M	-$1.65	N/A	N/A	N/A	N/A	-34.90%	-32.38%	8/6/2025 (Estimated)
CLSD Clearside Biomedical	-$32.49M	-$0.41	N/A	N/A	N/A	-413.83%	N/A	-92.90%	8/11/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
TERN Terns Pharmaceuticals	-$90.21M	-$1.09	N/A	N/A	N/A	N/A	-32.76%	-31.33%	8/4/2025 (Estimated)

Latest CLSD, CMPX, AVIR, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
3/27/2025	Q4 2024	CLSD Clearside Biomedical	-$0.13	-$0.10	+$0.03	-$0.10	$0.27 million	$0.31 million
3/20/2025	Q4 2024	TERN Terns Pharmaceuticals	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/6/2025	Q4 2024	AVIR Atea Pharmaceuticals	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.33	19.33
CLSD Clearside Biomedical	N/A	4.49	4.49
CMPX Compass Therapeutics	N/A	31.84	31.84
TERN Terns Pharmaceuticals	N/A	32.99	32.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CLSD Clearside Biomedical	18.75%
CMPX Compass Therapeutics	68.43%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
CLSD Clearside Biomedical	9.20%
CMPX Compass Therapeutics	29.80%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	69.43 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	68.87 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
TERN Terns Pharmaceuticals	40	87.34 million	72.11 million	Not Optionable

CLSD, CMPX, AVIR, and TERN Headlines

Recent News About These Companies

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

May 27 at 9:15 PM | investing.com

Nuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 27 at 3:53 AM | marketbeat.com

Northern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 26 at 3:02 AM | marketbeat.com

Deutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 25 at 3:30 AM | marketbeat.com

VR Adviser LLC Sells 2,332,968 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 22, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Position Cut by Point72 Asset Management L.P.

May 22, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 22, 2025 | marketbeat.com

BNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 22, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is Soleus Capital Management L.P.'s 10th Largest Position

May 21, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Graham Capital Management L.P.

May 17, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Parkman Healthcare Partners LLC

May 16, 2025 | marketbeat.com

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 16, 2025 | marketbeat.com

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025 | globenewswire.com

Terns Pharmaceuticals (NASDAQ:TERN) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

May 14, 2025 | marketbeat.com

Integral Health Asset Management LLC Increases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 14, 2025 | marketbeat.com

Dimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 13, 2025 | marketbeat.com

Driehaus Capital Management LLC Decreases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

May 12, 2025 | marketbeat.com

Why Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%

May 10, 2025 | aaii.com

Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?

May 9, 2025 | insidermonkey.com

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025 | globenewswire.com

Terns Pharmaceuticals (TERN) to Post Earnings on Monday

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, CMPX, AVIR, and TERN Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$2.95 +0.05 (+1.72%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.94 -0.01 (-0.17%)

As of 05/27/2025 04:04 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Clearside Biomedical NASDAQ:CLSD

$0.82 -0.04 (-5.02%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$0.81 -0.01 (-1.18%)

As of 05/27/2025 07:05 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Compass Therapeutics NASDAQ:CMPX

$2.11 +0.02 (+0.96%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.13 +0.02 (+1.18%)

As of 05/27/2025 07:52 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$3.01 -0.01 (-0.33%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$3.02 +0.02 (+0.50%)

As of 05/27/2025 05:23 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time